Navigation Links
Ardea Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference
Date:10/27/2010

s press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding our plans and goals, the expected properties and benefits of RDEA594, BAY 86-9766 (RDEA119), RDEA806, RDEA427 and our other compounds and the timing and results of our preclinical, clinical and other studies. Risks that contribute to the uncertain nature of the forward-looking statements include risks related to the outcome of preclinical and clinical studies, risks related to regulatory approvals, delays in commencement of preclinical and clinical studies, costs associated with our drug discovery and development programs, and risks related to the outcome of our business development activities, including collaboration or license agreements. These and other risks and uncertainties are described more fully in our most recently filed SEC documents, including our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q, under the headings "Risk Factors." All forward-looking statements contained in this press release speak only as of the date on which they were made.  We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

(Logo: http://photos.prnewswire.com/prnh/20091104/ARDEALOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20091104/ARDEALOGO)


'/>"/>
SOURCE Ardea Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors
2. Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference
3. Cardea Technology Inc and Optasia Medical Ltd Announce Plans to Collaborate to Optimize Their Vertebral Fracture Assessment Tools
4. Ardea Biosciences to Present at the UBS Global Life Sciences Conference and the Third Annual JMP Securities Healthcare Focus Conference
5. Ardea Biosciences to Present Data on Gout and Inflammation Programs at the 2008 ACR/ARHP Annual Scientific Meeting
6. Ardea Biosciences to Present Data on Lead MEK inhibitor, RDEA119, at EORTC-NCI-AACR Symposium
7. Regado Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference in New York City
8. GeneLink BioSciences, Inc. Ranked 62nd Fastest Growing Company in North America on Deloittes 2010 Technology Fast 500™
9. Sangamo BioSciences Announces Third Quarter 2010 Conference Call and Webcast
10. Neurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2010 Financial Results
11. Cell Biosciences to Acquire Convergent Bioscience
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... , ... August 27, 2015 , ... ... for venture capital funds, investment firms and animal health companies to hear from ... raised $160 million. Several have also received licensing agreements or distribution contracts. ...
(Date:8/27/2015)... Aug. 27, 2015  Neogen Corporation (NASDAQ: NEOG ... of United Kingdom -based Lab M ... media and diagnostic systems. Lab M ... leading provider of microbial testing and diagnostic products for ... The company currently sells into more than 70 countries ...
(Date:8/27/2015)... CELEBRATION, Fla. , Aug. 27, 2015 ... announced that a patient,s eyes—and life—were saved by doctors ... , working with NNFF, NovaBay Pharmaceuticals and Dr. ... Wound Care Center at Seton Medical Center in ... The successful treatment used a breakthrough approach, pioneered by ...
(Date:8/27/2015)... - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced ... 2015. Biorem,s complete second quarter financial statements and MD&A have been ... except earnings per shareThree-months ended , Six -months endedJune 30 , ... , 2014 Revenue , 4,709 , ... , 1,656 , 56 , 3,188 ...
Breaking Biology Technology:VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 2VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 3Neogen acquires U.K.-based Lab M Holdings 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 3BIOREM Reports $718,000 Net Earnings for the Second Quarter 2BIOREM Reports $718,000 Net Earnings for the Second Quarter 3
... FRANCISCO, Calif., May 8 Anesiva,Inc. (Nasdaq: ... and accomplishments,for the first quarter ended March ... its,commercialization activities for FDA-approved Zingo(TM) (lidocaine,hydrochloride monohydrate) ... development milestones for Adlea(TM), the company,s long-acting,localized, ...
... Pharmaceuticals,Inc. (NASDAQ: ANPI , TSX: ANP), a ... to participate in the Bank of America,2008 Health ... in Las Vegas,Nevada., Dr. William Hunter, Angiotech,s ... on Wednesday, May 14, beginning at approximately,4:00 pm ...
... highlights Volcano commitment to intravascular imaging ... opens up new clinical and research applications, ... Corporation (Nasdaq: VOLC ), a leading manufacturer ... and Optical,Coherence Tomography (OCT) products designed to enhance ...
Cached Biology Technology:Anesiva Announces First Quarter 2008 Financial Results 2Anesiva Announces First Quarter 2008 Financial Results 3Anesiva Announces First Quarter 2008 Financial Results 4Anesiva Announces First Quarter 2008 Financial Results 5Anesiva Announces First Quarter 2008 Financial Results 6Anesiva Announces First Quarter 2008 Financial Results 7Anesiva Announces First Quarter 2008 Financial Results 8Volcano Corp Announces First Human Use of the Volcano Optical Coherence Tomography (OCT) Imaging Catheter 2Volcano Corp Announces First Human Use of the Volcano Optical Coherence Tomography (OCT) Imaging Catheter 3Volcano Corp Announces First Human Use of the Volcano Optical Coherence Tomography (OCT) Imaging Catheter 4
(Date:8/19/2015)... , Aug. 19, 2015  VOXX International Corporation ... has entered into a Definitive Agreement to purchase ... iris authentication market leader EyeLock through an acquiring ... have a controlling interest in the acquiring entity. ... completion of due diligence.  Expanding on its existing ...
(Date:8/12/2015)... Minn. , Aug. 12, 2015   MedNet ... supports the entire spectrum of clinical research, is proud ... , the company,s comprehensive SaaS-based eClinical technology platform, has ... during the first two quarters of 2015.   Q2 ... second largest quarters measured by contract value sold in ...
(Date:8/11/2015)... Today, ZUK announced its Android smartphone Z1, ... expected revenues in 2015 that relate to sales of FPC1155 for ... approximately 2,200 MSEK for 2015. Jörgen Lantto, CEO of ... smartphone manufacturer in China and ... 155 for Z1 , ...
Breaking Biology News(10 mins):VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5MedNet Solutions Experiences Explosive Corporate Growth 2FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2
... This release is available in German . ... To defend themselves, they have developed sophisticated chemical defense ... cress ( Arabidopsis thaliana ), produce glucosinolates (mustard oil ... different kinds of these molecules; they have a similar ...
... such as the Japan earthquake can be revealed in ... to a psychology expert at Queen Mary, University of ... Mary, University of London, and author of Controlling Uncertainty: ... had a devastating immediate effect on tens of thousands ...
... Using skin cells from adult siblings with schizophrenia and ... researchers have created induced pluripotent stem cells (iPS cells) using ... February 22 in Molecular Psychiatry , the team confirms ... mutations in the gene named Disrupted In Schizophrenia 1, or ...
Cached Biology News:Production of mustard oils: On the origin of an enzyme 2Production of mustard oils: On the origin of an enzyme 3Psychological impact of Japan disaster will be felt 'for some time to come' 2Johns Hopkins team creates stem cells from schizophrenia patients 2Johns Hopkins team creates stem cells from schizophrenia patients 3
Anti-Phospho-JKK/SEK1/MKK4 pAb Description: 100 g rabbit polyclonal antibody. Reacts with human/mouse/rat. Tested in WB. Research Focus: signal transduction Storage: -20C Shipping Tem...
...
... pH This pH 9.9 solution is ... immunohistochemical staining procedures. It is for use ... glass slides. For particular antigens, target retrieval ... It should be noted that also endogenous ...
... very potent Rnase free Ribonuclease ... a broad range of temperatures ... does not inhibit SP6, T7, ... and M-MLV reverse transcriptase or ...
Biology Products: